Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study

Overview of attention for article published in Cancer Immunology, Immunotherapy, May 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

So far, Altmetric has seen 23 X posts from 18 X users, with an upper bound of 59,563 followers.

Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced uro… https://t.co/7rl0qYDFZK

RT @drenriquegrande: I know it’s not popular, particularly in absence of a good biomarker (PDL1 is not) but I think 🧐 there are patients wi…

RT @mjuanfi81: Let’s put this in context, with all the caveats that indirect comparisons between studies have, but to have it at a glance w…

RT @drenriquegrande: I know it’s not popular, particularly in absence of a good biomarker (PDL1 is not) but I think 🧐 there are patients wi…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 19 additional X posts.